Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.4K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

3.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.7K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

1.2K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.2K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.3K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.4K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same author

CholBindNet as an interpretable neural network for cholesterol-binding site classification.

Communications chemistry·2026
Same author

Yoda molecules agonize PIEZO2.

bioRxiv : the preprint server for biology·2026
Same author

A two-step clockwork mechanism opens a proteo-lipidic pore in PIEZO2.

Nature chemical biology·2026
Same author

Lipid-mediated gating of a miniature mechanosensitive MscS channel from Trypanosoma cruzi.

Nature communications·2025
Same author

Cmem Builder: An Automated Tool for Curved Membrane Construction in Molecular Dynamics Simulations.

Journal of chemical theory and computation·2025

Related Experiment Video

Updated: Oct 13, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

752

Mechanism-Based and Computational-Driven Covalent Drug Design.

Yun Lyna Luo1

  • 1Department of Pharmaceutical Sciences, Western University of Health Sciences, Pomona, California 91709, United States.

Journal of Chemical Information and Modeling
|November 10, 2021
PubMed
Summary

Covalent drugs show greater efficacy and duration. Advances in computational modeling of covalent drugs will revolutionize small molecule therapeutics, enabling mechanism-based rational drug design.

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

614
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Related Experiment Videos

Last Updated: Oct 13, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

752
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

614
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Covalent drugs offer superior efficacy and duration compared to noncovalent drugs.
  • Computational methods for modeling covalent drugs are rapidly advancing.

Purpose of the Study:

  • To discuss the advantages of computational models for covalent drugs.
  • To highlight opportunities for mechanism-based rational design.

Main Methods:

  • Review of computational modeling approaches for covalent ligands.
  • Discussion of two-state models for ranking ligands.
  • Exploration of complex models for reaction mechanism dissection.

Main Results:

  • Two-state models are advantageous for ranking reversible and irreversible covalent ligands.
  • Complex models aid in dissecting covalent drug binding mechanisms.
  • The relationship between models reveals the complexity of covalent binding.

Conclusions:

  • Computational modeling of covalent drugs is set to transform small molecule therapeutics.
  • Understanding covalent binding mechanisms enables rational drug design.
  • Diverse computational models offer opportunities for optimizing covalent drug development.